Re: AGM - Jan 7, 2016 - Details
in response to
by
posted on
Jan 08, 2016 01:38PM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
Thanks Masila. You rock! My favorite part:
"Q: Future of ZCC, especially what will be done with revenue streams?
A: Dividends, Dividends, Dividends. We aren’t contemplating any further investments. We already have ZEL and RVX. There’s 20 years of development effort at those two alone. We have our hands full."
BearDownAZ